Abiopharma

Alto Neuroscience, Inc. - Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203

Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203

Incyte Appoints Bill Meury Chief Executive Officer;Hervé Hoppenot to Retire

ProPhase Labs, Inc. Receives Additional 180 Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule

Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary

BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET

Aurora Expands Patient Access to Medical Cannabis in Canada with Extended Compassionate Pricing Program

Tilray Medical Publishes Pioneering Research on the Pharmacokinetics of THC and CBD Formulations

Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma

Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational Highlights